Health Trials

About this trial

The impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established. Patients undergoing cardiac surgery employing moderate hypothermic CPB are randomly allocated into one of two groups: in Group-ANH, ANH is applied by using a balanced hydroxyethyl starch (HES 130/0.6); and in Group-C, ANH is not applied. After weaning from CPB, intergroup differences of INTEM, EXTEM, FIBTEM, and APTEM profiles are analyzed. As a primary outcome, the inter-group differences between maximal clot firmness of EXTEM will be determined at 10 min after ANH in Group-ANH and that at control.

Eligibility criteria

Qualifiers

patients undergoing cardiac surgery with cardiopulmonary bypass who signed written informed consent

Disqualifiers

preoperative renal failure requiring reran replacement therapy

preoperative liver disease

preoperative low cardiac output (EF < 50%)

Preoperative IABP application, Atrial fibrillation, Pacemaker

Trial design

Treatments tested in this trial

  • Acute normovolemic hemodilution (ANH)
  • hydroxyethyl starch (HES 130/0.6)

Treatment groups

70 Participants
are divided into 2 treatment groups

Locations

2
Konkuk University Medical Center05030, SeoulSeoul, South Korea
Konkuk University Medical Center143-729, Seoul South Korea

Sponsors and collaborators

Konkuk University Medical Center

Lead sponsor

Source ClinicalTrials.gov